Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGFRvIII-targeted CAR-T cells
- Development stage
- Unknown
- Lead developer
- General Hospital of Central Theater Command of the Chinese People's Liberation Army
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intra-arterial
01
Overview
EGFRvIII-targeted CAR-T cells is an autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific mutation frequently expressed in glioblastoma and other advanced gliomas. Developed by Wuhan General Hospital of Guangzhou Command in collaboration with Shanghai GeneChem, the therapy is administered via vascular interventional therapy (intra-arterial infusion) to bypass the blood-brain barrier and enhance local delivery to the brain tumor site. It has been evaluated in a Phase 1 pilot study in China for the treatment of advanced EGFRvIII-positive brain glioma.
- Other names
- EGFRvIII CAR-TEGFRvIII CAR-T cellsEGFRvIII-targeted CAR-TEGFRvIII-targeted chimeric antigen receptor T cells
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on EGFRvIII-targeted CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGFRvIII-targeted CAR-T cells.